# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN
- Date: 2026-06-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-week check after the losartan increase and dapagliflozin start. **S**

## History of present illness

Mr. Washington returns three weeks after losartan was increased to 100 mg and dapagliflozin started. His home readings now run in the 140s and 150s over 90s. He has had no headaches for two weeks and palpitations are rare. He passes a little more urine in the daytime since starting dapagliflozin but has had no genital itching, thirst, or lightheadedness on standing. He has taken no pain relievers. On two trips he ate restaurant meals most days and has begun asking for dishes without added salt. **S**

| Element | Detail |
|---|---|
| Home blood pressure | 140s to 150s over 90s |
| Symptoms | No headaches for two weeks; palpitations rare |
| Medication tolerance | Slightly more daytime urine; no genital itching, thirst, or lightheadedness |
| Medicines | Every dose taken; no NSAIDs or other over-the-counter products |
| Diet | Asking for low-salt dishes on the road |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy slightly better; no weight change |
| Cardiovascular | Negative | No chest pain or ankle swelling; palpitations rare |
| Genitourinary | Positive | Slightly more daytime urine; up twice a night; no genital itching or dysuria |
| Neurological | Negative | No headache or lightheadedness on standing |
| Eyes | Negative | Reading blur unchanged; no sudden vision change |

5 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/92 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 70 kg; BMI 24.2 kg/m². All vital signs are synthetic.

Sodium: 137 mmol/L; Potassium: 4.9 mmol/L; Bicarbonate (total CO2): 22 mmol/L; BUN: 38 mg/dL (high); Creatinine: 2.4 mg/dL (high); eGFR: 30 mL/min/1.73 m² (low); Glucose: 94 mg/dL. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.9 mmol/L at this visit **S**
- Bicarbonate (total CO2): 21 mmol/L (low) at baseline, 22 mmol/L at this visit **S**
- BUN: 34 mg/dL (high) at baseline, 38 mg/dL (high) at this visit **S**
- Creatinine: 2.1 mg/dL (high) at baseline, 2.4 mg/dL (high) at this visit **S**
- eGFR: 36 mL/min/1.73 m² (low) at baseline, 30 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 94 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Blood pressure | 148/92 mmHg, the average of two seated readings after five minutes' rest |
| Heart | Regular rhythm, rate 78; S4 |
| Lungs | Clear |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe hypertension with hypertensive kidney disease, improving** (I12.9). Blood pressure 148/92 mmHg on full doses of amlodipine and losartan, still above target. **S**
   - Start chlorthalidone 12.5 mg daily as the third agent; potassium at the upper end of normal also favors a thiazide-like diuretic.
   - The sick-day rule now includes chlorthalidone.
2. **Chronic kidney disease stage G3b A3** (N18.32). Creatinine 2.4 mg/dL (up 14 percent from 2.1) and eGFR 30 (down 17 percent from 36), the expected early dip from losartan and dapagliflozin and within the 30 percent accepted. Potassium 4.9 mmol/L, bicarbonate 22. **S**
   - Continue losartan 100 mg and dapagliflozin 10 mg.
   - Potassium, sodium, and creatinine at the four-week check, with a urine albumin-creatinine ratio.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine (basic metabolic panel) | 2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR draw | Completed today | Three weeks after the losartan increase and dapagliflozin start. Potassium 4.9, creatinine 2.4 mg/dL (up 14 percent from baseline), eGFR 30 (down 17 percent), within the 30 percent accepted |
| Laboratory | Potassium, sodium, and creatinine after starting chlorthalidone | 2 to 4 weeks after a diuretic start | Due | Chlorthalidone starts today; drawn at the four-week check |
| Laboratory | eGFR and urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Due | Urine albumin-creatinine ratio at the four-week check, once the regimen is complete |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5 | Due | At the six-month review (deviation recorded last visit) |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 148/92 mmHg |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 70 kg; S4 |
| Medication safety | Dapagliflozin tolerance | Each visit while starting | Completed today | No genital infection, volume depletion, or lightheadedness |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs; doses checked for eGFR 30 |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Home log reviewed; low-salt choices on the road |

## Goal progress

- Lower blood pressure below 130/80 within two months. In progress; target 2026-06-29. **S**
- Reach a standardized office systolic pressure below 120 when tolerated by the six-month review. In progress; target 2026-10-26. **S**
- Reduce the urine albumin-creatinine ratio by at least 30 percent by the six-month review. In progress; target 2026-10-26. **S**
- Keep eGFR decline after starting therapy within 30 percent and stable thereafter. In progress; target 2026-10-26. **S**

## Medication changes

- Started: Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (KDIGO)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (KDIGO)
- CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026), Aether Forge

## Follow-up

- Four-week check with potassium, sodium, creatinine, and a urine albumin-creatinine ratio after starting chlorthalidone. **S**
- Next scheduled visit 2026-06-29: four-week check after adding chlorthalidone. **S**
